Corneal edema is refer to a cornea that is excessively hydrated than the normal 78% water content. Excess hydration of cornea causes to loss transparency of cornea and leads to impaired vision and eye pain. The corneal edema treatment choice is depends on the specific cause and related symptoms of an individual patient. Elimination of the underlying aetiology must be targeted in the case of secondary edema (inflammation, infection, trauma, glaucoma). Topical corticosteroids and hypertonic agent are considered to be primary treatment therapies. Topical corticosteroids reduces anterior segment inflammation and consequently corneal edema. Other complications is increase in intraocular pressure, which can be treated using hypertonic agent, carbonic anhydrase inhibitors. Antibiotic therapies can be preferred in case of infection based corneal edema. For management of primary corneal edema, hypertonic agent in the form of topical drops and ointment can be prefer to treat mild edema which draw out excessive corneal fluid. In addition, bandage contact lens on cornea can be used as an auxiliary treatments to provide relief from discomfort of edema when surgical intervention is not recommended or is delayed. In case of high-risk chronic corneal edema, surgical corneal transplantation treatment can be performed to improve vision of the patient.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-10832
Corneal Edema Treatment Market: Drivers and Restraints
Corneal edema treatment market is expected to witness high growth owing to increasing aging population and rise in eye disease prevalence. From patient perspective, increasing clinical research and subsequent new product launch is expected to fuel the corneal edema treatment market. Increasing number of corneal trauma from cataract surgeries and accidents is a major driving factor of corneal edema treatment market. However, low healthcare expenditure are expected to hamper the future corneal edema treatment market in developing economies. Also, less awareness among the patient about the treatment option may deter the progress of corneal edema treatment market.
Corneal Edema Treatment Market: Overview
The global corneal edema treatment market is estimated to grow steady growth over forecast years owing to global rise in aging populations, increasing number of surgical procedures associated with eye disease epidemic. According to WHO, glaucoma is second leading cause of blindness globally which needs corneal edema prone surgical procedures. In corneal treatment market, topical corticosteroids and hypertonic agents therapies are expected to grow with high rate owing to their use in first-line treatment in acute as well chronic conditions of corneal edema. Recently, DEXTENZA, a dexamethasone corticosteroid containing advanced delivery ophthalmic insert manufactured by Ocular Therapeutics is approved by US FDA. However, corneal devices and transplantations associated post use/surgery risk is hampering their preference in treatment options.
Corneal Edema Treatment Market: Regional Outlook
The global corneal edema treatment market is expected to be dominated by North America due to higher product research and development activities with existing product availability. Europe is expected to be the second most growing region in the global corneal edema treatment market owing to advancements in early diagnosis and treatment. Latin America is emerging region for corneal edema treatment market and is estimated to show exponential growth owing to high product availability. East-Asia corneal edema treatment market is expected to show significant growth as high prevalence. Middle East & Africa is expected to be the least lucrative region in the corneal edema treatment market due to least product adoption and standard diagnosis and treatment seeking rate.
Corneal Edema Treatment Market: Key Players
The key players operating in the global corneal edema treatment market are: Pfizer Inc., Abbvie Inc, Novartis, Hoffmann-La Roche Ltd., Allergan, Bayer AG, Bausch & Lomb Incorporated, Johnson & Johnson, Teva Pharmaceuticals, Sun Pharmaceutical and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-10832
Why Future Market Insights?
- Comprehensive analysis on evolving purchase pattern across different geographies
- Detailed insights of market segments and sub-segments for historical as well as forecast period
- A competitive analysis of prominent players and emerging players in the keyword market
- Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: email@example.com
For Media Enquiries: firstname.lastname@example.org